跳到主要內容

臺灣博碩士論文加值系統

(3.236.124.56) 您好!臺灣時間:2021/08/02 07:31
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:郭博仁
研究生(外文):Kuo, Po-Jen
論文名稱:利用人類牙齦纖維細胞與U937巨噬細胞共同培養技術,探討環胞靈在P.g酯多醣體刺激環境下對於第二型及第九型基質金屬蛋白酶活性之抑制
論文名稱(外文):Cyclosporine-A Inhibits MMP-2 And MMP-9 Activities In The Presence Of P. gingivalis Lipopolysaccharide: An Experiment In Human Gingival Fibroblast And U937 Marcrophage Co-culture
指導教授:傅鍔傅鍔引用關係
指導教授(外文):Fu, Earl
口試委員:江正陽涂筱培沈一慶聶鑫
口試委員(外文):Chiang, Cheng-YangTu, Hsiao-PeiShen, E-ChinNieh, Shin
口試日期:2011-05-31
學位類別:碩士
校院名稱:國防醫學院
系所名稱:牙醫科學研究所
學門:醫藥衛生學門
學類:牙醫學類
論文種類:學術論文
論文出版年:2012
畢業學年度:100
語文別:中文
論文頁數:67
中文關鍵詞:環胞靈基質金屬蛋白酶纖維母細胞巨噬細胞
外文關鍵詞:cyclosporineMMPfibroblastmacrophage
相關次數:
  • 被引用被引用:0
  • 點閱點閱:247
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
目前研究發現臨床上牙菌斑堆積及牙齦組織發炎刺激會對於環胞靈(cyclosporin-A(CsA))造成之牙齦腫大有加成性的影響,但CsA造成牙齦腫大的成因及牙周組織破壞間的關聯仍不清楚,其中CsA影響基質金屬蛋白酶(matrix metalloproteinases(MMPs))的調節被認為扮演重要的腳色;本實驗利用共同培養人類初級培養纖維母細胞 (human gingival epithelial cell(HGF))以及U937人類巨噬細胞株,來探究CsA及病菌酯多醣體(lipopolysaccharide(LPS))對於共同培養環境中基質金屬蛋白酶酵素活性的影響。
實驗中利用個別獨立培養(independent cultures)及共同培養(co-cultures)人類初級培養纖維母細胞以及U937人類巨噬細胞株,分別給與不同濃度的環胞靈以及P.g 菌酯多醣體(P. gingivalis LPS.),處理24及48小時之後,收取上層細胞培養液進行蛋白酵素電泳法,測定第二型、第九型基質金屬蛋白酶(MMP-2、MMP-9)之活性。
實驗結果顯示共同培養與獨立培養做比較,兩種細胞共同培養時第二型、第九型基質金屬蛋白酶(MMP-2、MMP-9)之活性有顯著的增加;在酯多醣體(LPS)刺激下,共同培養環境中基質金屬蛋白酶活性隨著濃度提升而增加,且有顯著劑量依賴性(dose-dependent manner),另一方面環胞靈對於基質金屬蛋白酶活性有著劑量依賴性的抑制效果;不論有無酯多醣體存在,於共同培養環境中都可發現環胞靈能顯著抑制第二型、第九型基質金屬蛋白酶的活性,然而在獨立培養環境中在存在酯多醣體刺激下,環胞靈同時對於兩種基質金屬蛋白酶活性的抑制,卻不能被同時觀測到
本實驗結果顯示在共同培養人類初級培養纖維母細胞以及人類巨噬細胞株情況下,即使存在酯多醣體的刺激,環胞靈對於基質金屬蛋白酶活性依然具有顯著的抑制;因此我們推論即使有細菌牙菌斑堆積及牙周區域性發炎存在時,環胞靈引起的牙齦腫大依然持續存在。
目前研究發現臨床上牙菌斑堆積及牙齦組織發炎刺激會對於環胞靈(cyclosporin-A(CsA))造成之牙齦腫大有加成性的影響,但CsA造成牙齦腫大的成因及牙周組織破壞間的關聯仍不清楚,其中CsA影響基質金屬蛋白酶(matrix metalloproteinases(MMPs))的調節被認為扮演重要的腳色;本實驗利用共同培養人類初級培養纖維母細胞 (human gingival epithelial cell(HGF))以及U937人類巨噬細胞株,來探究CsA及病菌酯多醣體(lipopolysaccharide(LPS))對於共同培養環境中基質金屬蛋白酶酵素活性的影響。
實驗中利用個別獨立培養(independent cultures)及共同培養(co-cultures)人類初級培養纖維母細胞以及U937人類巨噬細胞株,分別給與不同濃度的環胞靈以及P.g 菌酯多醣體(P. gingivalis LPS.),處理24及48小時之後,收取上層細胞培養液進行蛋白酵素電泳法,測定第二型、第九型基質金屬蛋白酶(MMP-2、MMP-9)之活性。
實驗結果顯示共同培養與獨立培養做比較,兩種細胞共同培養時第二型、第九型基質金屬蛋白酶(MMP-2、MMP-9)之活性有顯著的增加;在酯多醣體(LPS)刺激下,共同培養環境中基質金屬蛋白酶活性隨著濃度提升而增加,且有顯著劑量依賴性(dose-dependent manner),另一方面環胞靈對於基質金屬蛋白酶活性有著劑量依賴性的抑制效果;不論有無酯多醣體存在,於共同培養環境中都可發現環胞靈能顯著抑制第二型、第九型基質金屬蛋白酶的活性,然而在獨立培養環境中在存在酯多醣體刺激下,環胞靈同時對於兩種基質金屬蛋白酶活性的抑制,卻不能被同時觀測到
本實驗結果顯示在共同培養人類初級培養纖維母細胞以及人類巨噬細胞株情況下,即使存在酯多醣體的刺激,環胞靈對於基質金屬蛋白酶活性依然具有顯著的抑制;因此我們推論即使有細菌牙菌斑堆積及牙周區域性發炎存在時,環胞靈引起的牙齦腫大依然持續存在。

Background and Objective:
Studies have shown that the bacterial plaque and the associated gingival inflammation increase the severity of gingival overgrowth induced by cyclosporin-A (CsA). This in vitro study evaluated the effect of CsA on the activities of matrix metalloproteinases (MMPs), including pro-MMP-2, MMP-2 and pro-MMP-9, from the co-culture of human gingival fibroblasts and U937 macrophages in presence of Porphyromonas gingivalis lipopolysaccharide (LPS).
Material and Methods:
Gelatinolytic activities of pro-MMP-2, MMP-2, and pro-MMP-9, in the supernatants of independent cultures and co-cultures of human gingival fibroblasts and U-937 macrophages cell line in the presence or absence of P. gingivalis LPS.
Results:
Activities of MMPs in the co-cultures were significantly greater if compared to any of independent cultures. LPS significantly increased the MMP activities in a dose-dependent manner in the co-cultures, whereas CsA inhibited these activities. In the presence of both CsA and LPS, the inhibited MMP activities by CsA could still be observed in the co-cultures. In the individual culture of fibroblasts or U937, nevertheless, the CsA-inhibited MMP activities, in the presence of LPS, were not consistently observable.
Conclusion:
This study demonstrated that, in the co-cultures of human gingival fibroblasts and U937 macrophages, CsA could inhibit MMP activities in the presence of P. gingivalis LPS. It might be part of the underlying reason for the persistent overgrowth of gingiva seen when bacterial plaque and local inflammation are present during the CsA therapy.

壹、 緒論 2
一、 環胞靈 2
二、 基質金屬蛋白酶 18
三、 研究目的 20
貳、 材料與方法 24
一、主要儀器與藥品試劑 24
二、主要實驗方法與步驟 26
參、 實驗結果 33
肆、 實驗討論 35
伍、 結論 40
陸、 參考文獻 46
柒、 附錄 65


1.Abe M, Yokoyama Y, Syuto T, Ishibuchi H, Ishikawa O:Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts. Cell Tissue Res 333:281-288, 2008.
2.Adams D, Davies G:Gingival hyperplasia associated with cyclosporin A. A report of two cases. Br Dent J 157:89-90, 1984.
3.Allison MC, Pounder RE:Cyclosporin for Crohn's disease. Lancet 1:902-903, 1984.
4.Arora PD, Silvestri L, Ganss B, Sodek J, McCulloch CA:Mechanism of cyclosporin-induced inhibition of intracellular collagen degradation. J Biol Chem 276:14100-14109, 2001.
5.Atilla G, Sorsa T, Ronka H, Emingil G:Matrix metalloproteinases (MMP-8 and -9) and neutrophil elastase in gingival crevicular fluid of cyclosporin-treated patients. J Periodontol 72:354-360, 2001.
6.Bartold PM:Regulation of human gingival fibroblast growth and synthetic activity by cyclosporine-A in vitro. J Periodontal Res 24:314-321, 1989.
7.Bartold PM:Regulation of human gingival fibroblast growth and synthetic activity by cyclosporine-A in vitro. J Periodont Res 24:314-321, 1989.
8.Bendtzen K, Tvede N, Andersen V, Bendixen G:Cyclosporin for polymyositis. Lancet 1:792-793, 1984.
9.Beveridge T, Gratwohl, A. &Michot, F.:Cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone marrow grafts. Current Therapeutics Research 30:5, 1981.
10.Biren CA, Barr RJ:Dermatologic applications of cyclosporine. Arch Dermatol 122:1028-1032, 1986.
11.Birkedal-Hansen H, Moore WG, Bodden MK, et al.:Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197-250, 1993.
12.Biswas C, Zhang Y, DeCastro R, et al.:The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55:434-439, 1995.
13.Bodet C, Andrian E, Tanabe S, Grenier D:Actinobacillus actinomycetemcomitans lipopolysaccharide regulates matrix metalloproteinase, tissue inhibitors of matrix metalloproteinase, and plasminogen activator production by human gingival fibroblasts: a potential role in connective tissue destruction. J Cell Physiol 212:189-194, 2007.
14.Bodet C, Chandad F, Grenier D:Inhibition of host extracellular matrix destructive enzyme production and activity by a high-molecular-weight cranberry fraction. J Periodont Res 42:159-168, 2007.
15.Bolzani G, Della Coletta R, Martelli Junior H, Graner E:Cyclosporin A inhibits production and activity of matrix metalloproteinases by gingival fibroblasts. J Periodontal Res 35:51-58, 2000.
16.Bordador LC, Li X, Toole B, et al.:Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 85:347-352, 2000.
17.Borel JF, Feurer C, Gubler HU, Stahelin H:Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6:468-475, 1976.
18.Bostrom A, Bharath H, Saulewicz A, Narayanan AS:Cyclosporin a affects signaling events differentially in human gingival fibroblasts. J Dent Res 84:532-536, 2005.
19.Brayman KL, Armstrong J, Shaw LM, et al.:Prevention of diabetes in BB rats by intermittent administration of cyclosporine. Surgery 102:235-241, 1987.
20.Brinckerhoff CE, Rutter JL, Benbow U:Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830, 2000.
21.Britton S, Palacios R:Cyclosporin A--usefulness, risks and mechanism of action. Immunol Rev 65:5-22, 1982.
22.Buduneli E, Genel F, Atilla G, Kutukculer N:Evaluation of p53, bcl-2, and interleukin-15 levels in gingival crevicular fluid of cyclosporin A-treated patients. J Periodontol 74:506-511, 2003.
23.Buduneli N, Kutukculer N, Aksu G, Atilla G:Evaluation of transforming growth factor-beta 1 level in crevicular fluid of cyclosporin A-treated patients. J Periodontol 72:526-531, 2001.
24.Buduneli N, Sagol O, Atilla G, Duman S, Holmstrup P:Immunohistochemical analysis of epidermal growth factor receptor in cyclosporin A-induced gingival overgrowth. Acta Odontol Scand 59:367-371, 2001.
25.Bueding E, Hawkins J, Cha YN:Antischistosomal effects of cyclosporin A. Agents Actions 11:380-383, 1981.
26.Bulut OE, Sokmensuer LK, Bulut S, Tasman F, Muftuoglu S:Immunohistochemical study of cyclosporin-induced gingival overgrowth in renal transplant recipients. J Periodontol 75:1655-1662, 2004.
27.Bulut S, Ozdemir BH, Alaaddinoglu EE, Oduncuoglu FB, Bulut OE, Demirhan B:Effect of cyclosporin A on apoptosis and expression of p53 and bcl-2 proteins in the gingiva of renal transplant patients. J Periodontol 76:691-695, 2005.
28.Cadranel JF, Grippon P, Mattei MF, et al.:Prevalence and causes of long-lasting hepatic dysfunction after heart transplantation: a series of 80 patients. Artif Organs 12:234-238, 1988.
29.Calne RY, Rolles K, White DJ, et al.:Cyclosporin-A in clinical organ grafting. Transplant Proc 13:349-358, 1981.
30.Calne RY, Rolles K, White DJ, et al.:Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2:1033-1036, 1979.
31.Calne RY, White DJ, Thiru S, et al.:Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2:1323-1327, 1978.
32.Campistol JM, Sacks SH:Mechanisms of nephrotoxicity. Transplantation 69:SS5-10, 2000.
33.Cetinkaya BO, Acikgoz G, Ayas B, Aliyev E, Sakallioglu EE:Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats. J Periodontol 77:54-60, 2006.
34.Cetinkaya BO, Acikgoz G, Aydin O, Korkmaz A, Keles GC:The relationship between proliferating cell nuclear antigen expression and histomorphometrical alterations in cyclosporin A-induced gingival overgrowth in rats. Toxicol Pathol 34:180-186, 2006.
35.Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T:Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285, 2003.
36.Chen YT, Tu HP, Chin YT, et al.:Upregulation of Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor Gene and Protein Expression in Cyclosporin-Induced Overgrown Edentulous Gingiva in Rats. J Periodontol 76:2267-2275, 2005.
37.Chin YT, Chen YT, Tu HP, et al.:Upregulation of the expression of epidermal growth factor and its receptor in gingiva upon cyclosporin a treatment. J Periodontol 77:647-656, 2006.
38.Chiu HC, Lu YT, Chin YT, et al.:Cyclosporine A inhibits the expression of membrane type-I matrix metalloproteinase in gingiva. J Periodont Res 44:338-347, 2009.
39.Collier IE, Wilhelm SM, Eisen AZ, et al.:H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263:6579-6587, 1988.
40.Cotrim P, de Andrade CR, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD:Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor (TGF)-beta1 autocrine stimulation. J Periodontol 73:1313-1322, 2002.
41.Cotrim P, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD:Cyclosporin A induces proliferation in human gingival fibroblasts via induction of transforming growth factor-beta1. J Periodontol 74:1625-1633, 2003.
42.Dannewitz B, Edrich C, Tomakidi P, et al.:Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth. Cell Tissue Res, 2006.
43.Das SJ, Parkar MH, Olsen I:Upregulation of keratinocyte growth factor in cyclosporin A-induced gingival overgrowth. J Periodontol 72:745-752, 2001.
44.Deliliers GL, Santoro F, Polli N, Bruno E, Fumagalli L, Risciotti E:Light and electron microscopic study of cyclosporin A-induced gingival hyperplasia. J Periodontol 57:771-775, 1986.
45.Egeblad M, Werb Z:New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002.
46.Ejeil AL, Igondjo-Tchen S, Ghomrasseni S, Pellat B, Godeau G, Gogly B:Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in healthy and diseased human gingiva. J Periodontol 74:188-195, 2003.
47.Feutren G, Querin S, Noel LH, et al.:Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 111:1063-1068, 1987.
48.Fingleton B, Matrisian LM:Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol 13:368-373, 2001.
49.Foda HD, Rollo EE, Drews M, et al.:Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Am J Respir Cell Mol Biol 25:717-724, 2001.
50.Frecnch-Constant C, Wolman J, Geraaint JD:Cyclosporin in Behcet's disease. Lancet 2:454-455, 1983.
51.Friskopp J, Klintmalm G:Gingival enlargement. A comparison between cyclosporine and azathioprine treated renal allograft recipients. Swed Dent J 10:85-92, 1986.
52.Fu E, Hsieh YD, Shen EC, Nieh S, Mao TK, Chiang CY:Cyclosporin-induced gingival overgrowth at the newly formed edentulous ridge in rats: a morphological and histometric evaluation. J Periodontol 72:889-894, 2001.
53.Fu E, Nieh S, Chang HL, Wang SL:Dose-dependent gingival overgrowth induced by cyclosporin in rats. J Periodontol 66:594-598, 1995.
54.Fu E, Nieh S, Wikesjo UM:The effect of plaque retention on cyclosporine-induced gingival overgrowth in rats. J Periodontol 68:92-98, 1997.
55.Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S:EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87:361-368, 2005.
56.Gagliano N, Moscheni C, Torri C, et al.:Differential effect of Cyclosporin A and FK506 on SPARC mRNA expression by human gingival fibroblasts. Biomed Pharmacother 59:249-252, 2005.
57.Gau CH, Chou TC, Chiu HC, et al.:Effect of cyclosporin A on the expression of inducible nitric oxide synthase in the gingiva of rats. J Periodontol 76:2260-2266, 2005.
58.Gnoatto N, Lotufo RF, Toffoletto O, Marquezini MV:Gene expression of extracellular matrix proteoglycans in human cyclosporin-induced gingival overgrowth. J Periodontol 74:1747-1753, 2003.
59.Gross J, Lapiere CM:Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 48:1014-1022, 1962.
60.Guo H, Zucker S, Gordon MK, Toole BP, Biswas C:Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 272:24-27, 1997.
61.Gupta S, Keshavarzian A, Hodgson HJ:Cyclosporin in ulcerative colitis. Lancet 2:1277-1278, 1984.
62.Hansen JM, Christensen NJ, Fogh-Andersen N, Strandgaard S:Effects of the prostacyclin analogue iloprost on cyclosporin-induced renal hypoperfusion in stable renal transplant recipients. Nephrol Dial Transplant 11:340-346, 1996.
63.Hassell TM, Romberg E, Sobhani S, Lesko L, Douglas R:Lymphocyte-mediated effects of cyclosporine on human fibroblasts. Transplant Proc 20:993-1002, 1988.
64.Hess A, D, Tutschka, P J, & Santos, G. W,:The effect of cyclosporin A on T-lymphocyte subpopulations. In: Cyclosporin A, ed, D, J, G, White :209-232, 1982.
65.Hess AD, Colombani PM:Mechanism of action of cyclosporine: a unifying hypothesis. Adv Exp Med Biol 213:309-330, 1987.
66.Hojo M, Morimoto T, Maluccio M, et al.:Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534, 1999.
67.Huhtala P, Chow LT, Tryggvason K:Structure of the human type IV collagenase gene. J Biol Chem 265:11077-11082, 1990.
68.Hyland PL, McKeown ST, Mackenzie IC, Irwin CR:Regulation of keratinocyte growth factor and scatter factor in cyclosporin-induced gingival overgrowth. J Oral Pathol Med 33:391-397, 2004.
69.Hyland PL, Traynor PS, Myrillas TT, et al.:The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. J Periodontol 74:437-445, 2003.
70.Jensen JR, Thestrup-Pedersen K, Zachariae H, Sogaard H:Cyclosporin A therapy for mycosis fungoides. Arch Dermatol 123:160-163, 1987.
71.Kanekura T, Chen X, Kanzaki T:Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99:520-528, 2002.
72.Kataoka M, Seto H, Wada C, Kido J, Nagata T:Decreased expression of alpha2 integrin in fibroblasts isolated from cyclosporin A- induced gingival overgrowth in rats. J Periodontal Res 38:533-537, 2003.
73.Kataoka M, Shimizu Y, Kunikiyo K, et al.:Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol 182:351-358, 2000.
74.Kelly EA, Jarjour NN:Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med 9:28-33, 2003.
75.Kim JH, Perfect JR:Infection and cyclosporine. Rev Infect Dis 11:677-690, 1989.
76.Klintmalm GB, Iwatsuki S, Starzl TE:Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 32:488-489, 1981.
77.Kobashigawa JA, Kasiske BL:Hyperlipidemia in solid organ transplantation. Transplantation 63:331-338, 1997.
78.Koh JT, Kim OJ, Park YS, et al.:Decreased expressions of thrombospondin 2 in cyclosporin A-induced gingival overgrowth. J Periodontal Res 39:93-100, 2004.
79.Krensky AM ST, Bluestone JA:Immunomodulators:immunosuppressive agents, tolerogens and immunostimulants. In Goodman & Gilam’s The Pharmacological Basis of Therapeutics 10th ed New York: McGraw-Hill Companies, Inc :1465, 2001.
80.Kusano K, Miyaura C, Inada M, et al.:Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139:1338-1345, 1998.
81.Lijnen HR:Extracellular proteolysis in the development and progression of atherosclerosis. Biochem Soc Trans 30:163-167, 2002.
82.Lind M, Trindade MC, Yaszay B, Goodman SB, Smith RL:Effects of particulate debris on macrophage-dependent fibroblast stimulation in coculture. J Bone Joint Surg Br 80:924-930, 1998.
83.Mariotti A, Hassell T, Jacobs D, Manning CJ, Hefti AF:Cyclosporin A and hydroxycyclosporine (M-17) affect the secretory phenotype of human gingival fibroblasts. J Oral Pathol Med 27:260-266, 1998.
84.Markopoulos AK, Belazi M, Drakoulakos D, et al.:Epidermal growth factor in saliva and serum of patients with cyclosporin-induced gingival overgrowth. J Periodontal Res 36:88-91, 2001.
85.Marley JJ, Phenix KV, Irwin CR, Thompson J, Robinson PA, Linden GJ:Signal recognition particle receptor (SRPR) is downregulated in a rat model of cyclosporin A-induced gingival overgrowth. J Periodontal Res 34:188-196, 1999.
86.Marshall RI, Bartold PM:A clinical review of drug-induced gingival overgrowths. Aust Dent J 44:219-232, 1999.
87.Maurer G:Metabolism of cyclosporine. Transplant Proc 17:19-26, 1985.
88.McCulloch CA, Knowles GC:Deficiencies in collagen phagocytosis by human fibroblasts in vitro: a mechanism for fibrosis? J Cell Physiol 155:461-471, 1993.
89.McGregor AM, Beck L, Hall R:Cyclosporin A in management of Graves' disease. J R Soc Med 78:511-512, 1985.
90.Morisaki I, Akiyama YM, Miyawaki YN, Mori Y:Positive correlation between blood cyclosporin A level and severity of gingival overgrowth in rats. J Periodontol 68:7-11, 1997.
91.Morton RS, Dongari-Bagtzoglou AI:Regulation of gingival fibroblast interleukin-6 secretion by cyclosporine A. J Periodontol 70:1464-1471, 1999.
92.Muller W, Herrmann B:Influence of cyclosporin A on psoriasis. Dtsch Med Wochenschr 104:1047, 1979.
93.Myrillas TT, Linden GJ, Marley JJ, Irwin CR:Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. J Periodontol 70:294-300, 1999.
94.Nagase H:Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160, 1997.
95.Nassar CA, Nassar PO, Abi Rached RS, Holzhausen M, Marcantonio E, Jr., Spolidorio LC:Effect of cyclosporin A on alveolar bone homeostasis in a rat periodontitis model. J Periodont Res 39:143-148, 2004.
96.Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K:Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 28:671-679, 1985.
97.Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I:Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 2:235-238, 1983.
98.Opelz G, Schwarz V, Henderson R, Kneifel G, Ruhenstroth A:Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant year. Transpl Int 7 Suppl 1:S353-356, 1994.
99.Palestine AG, Nussenblatt RB, Chan CC:Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 77:652-656, 1984.
100.Paller MS, Murray BM:Renal dysfunction in animal models of cyclosporine toxicity. Transplant Proc 17:155-159, 1985.
101.Parkar MH, Hussain F, Wickramaratna A, Olsen I:The immunosuppressant and hyperplasia-inducing drug cyclosporin A regulates the cell cycle and cyclin B1 gene expression in gingival fibroblasts in vitro. Cell Tissue Res 317:221-225, 2004.
102.Parodi A, Rebora A:Topical cyclosporine in alopecia areata. Arch Dermatol 123:165-166, 1987.
103.Patel JK, Kobashigawa JA:Cardiac transplant experience with cyclosporine. Transplant Proc 36:323S-330S, 2004.
104.Petcher TJ, Weber H, Ruegger A:Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv Chim Acta 59:1480-1489, 1976.
105.Pilatti GL, Sampaio JE:The influence of chlorhexidine on the severity of cyclosporin A-induced gingival overgrowth. J Periodontol 68:900-904, 1997.
106.Puttick L, Pollock A, Fairburn E:Treatment of Sezary syndrome with cyclosporin A. J R Soc Med 76:1063-1065, 1983.
107.Rateitschak-Pluss EM, Hefti A, Lortscher R, Thiel G:Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 10:237-246, 1983.
108.Rebuck AS, Stiller CR, Braude AC, Laupacis A, Cohen RD, Chapman KR:Cyclosporin for pulmonary sarcoidosis. Lancet 1:1174, 1984.
109.Reynolds NJ, Al-Daraji WI:Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 27:555-561, 2002.
110.Rostock MH, Fry HR, Turner JE:Severe gingival overgrowth associated with cyclosporine therapy. J Periodontol 57:294-299, 1986.
111.Routhier G, Epstein O, Janossy G, et al.:Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet 2:1223-1226, 1980.
112.Ruhl S, Hamberger S, Betz R, et al.:Salivary proteins and cytokines in drug-induced gingival overgrowth. J Dent Res 83:322-326, 2004.
113.Rundhaug JE:Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267-285, 2005.
114.Schincaglia GP, Forniti F, Cavallini R, Piva R, Calura G, del Senno L:Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 21:181-185, 1992.
115.Seymour RA, Smith DG:The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol 18:107-110, 1991.
116.Shankavaram UT, Lai WC, Netzel-Arnett S, et al.:Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 276:19027-19032, 2001.
117.Shaw LM:Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring. Clin Chem 35:1299-1308, 1989.
118.Sigal NH, Dumont FJ:Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10:519-560, 1992.
119.Spolidorio LC, Holzhausen M, Spolidorio DM, Nassar CA, Nassar PO, Muscara MN:Cyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats. J Periodontol 76:1520-1525, 2005.
120.Starzl TE, Weil R, 3rd, Iwatsuki S, et al.:The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 151:17-26, 1980.
121.Stetler-Stevenson WG, Krutzsch HC, Liotta LA:Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264:17374-17378, 1989.
122.Stiller CR, Laupacis A, Dupre J, et al.:Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med 308:1226-1227, 1983.
123.Stryckmans PA, Dumont JP, Velu T, Debusscher L:Cyclosporine in refractory severe aplastic anemia. N Engl J Med 310:655-656, 1984.
124.Sugano N, Ito K, Murai S:Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. J Periodontal Res 33:448-452, 1998.
125.Sundararaj KP, Samuvel DJ, Li Y, Sanders JJ, Lopes-Virella MF, Huang Y:Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: cross-talking between fibroblasts and U937 macrophages exposed to high glucose. J Biol Chem 284:13714-13724, 2009.
126.Sundstrom C, Nilsson K:Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565-577, 1976.
127.Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A:Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1:334-335, 1985.
128.Thomason JM, Sloan P, Seymour RA:Immunolocalization of collagenase (MMP-1) and stromelysin (MMP-3) in the gingival tissues of organ transplant patients medicated with cyclosporin. J Clin Periodontol 25:554-560, 1998.
129.Thommen-Scott K:Antimalarial activity of cyclosporin A. Agents Actions 11:770-773, 1981.
130.Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G:Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719-724, 1987.
131.Totterman TH, Scheynius A, Killander A, Danersund A, Alm GV:Treatment of therapy-resistant Sezary syndrome with Cyclosporin-A: suppression of pruritus, leukaemic T cell activation markers and tumour mass. Scand J Haematol 34:196-203, 1985.
132.Tyldesley WR, Rotter E:Gingival hyperplasia induced by cyclosporin-A. Br Dent J 157:305-309, 1984.
133.van Joost T, Stolz E, Heule F:Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 123:166-167, 1987.
134.Vardar S, Baylas H, Zihnioglu F, Buduneli N, Emingil G, Atilla G:Gingival tissue proteoglycan and chondroitin-4-sulphate levels in cyclosporin A-induced gingival overgrowth and the effects of initial periodontal treatment. J Clin Periodontol 32:634-639, 2005.
135.Varga E, Lennon MA, Mair LH:Pre-transplant gingival hyperplasia predicts severe cyclosporin-induced gingival overgrowth in renal transplant patients. J Clin Periodontol 25:225-230, 1998.
136.Velthuis PJ, Jesserun RF:Improvement of ichthyosis by cyclosporin. Lancet 1:335, 1985.
137.Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW:Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 12:375-381, 1997.
138.Vincenti MP, Brinckerhoff CE:Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4:157-164, 2002.
139.von Wartburg A, Traber R:Chemistry of the natural cyclosporin metabolites. Prog Allergy 38:28-45, 1986.
140.Wentzell JM, Baughman RD, O'Connor GT, Bernier GM, Jr.:Cyclosporine in the treatment of psoriasis. Arch Dermatol 123:163-165, 1987.
141.Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI:SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264:17213-17221, 1989.
142.Willershausen-Zonnchen B, Lemmen C, Schumacher U:Influence of cyclosporine A on growth and extracellular matrix synthesis of human fibroblasts. J Cell Physiol 152:397-402, 1992.
143.Wondimu B, Dahllof G, Berg U, Modeer T:Cyclosporin-A-induced gingival overgrowth in renal transplant children. Scand J Dent Res 101:282-286, 1993.
144.Woolfson RG, Neild GH:Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 12:2054-2056, 1997.
145.Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR:Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol 55:274-278, 1983.
146.Yamada H, Nishimura F, Naruishi K, et al.:Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol 71:955-960, 2000.
147.Yamaguchi M, Naruishi K, Yamada-Naruishi H, Omori K, Nishimura F, Takashiba S:Long-term cyclosporin A exposure suppresses cathepsin-B and -L activity in gingival fibroblasts. J Periodontal Res 39:320-326, 2004.
148.Yang Y, Lu N, Zhou J, Chen ZN, Zhu P:Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 47:1299-1310, 2008.
149.Yoshida T, Nagata J, Yamane A:Growth factors and proliferation of cultured rat gingival cells in response to cyclosporin A. J Periodontal Res 40:11-19, 2005.
150.Zabel P, Leimenstoll G, Gross WL:Cyclosporin for acute dermatomyositis. Lancet 1:343, 1984.
151.Zebrowski EJ, Pylypas SP, Odlum O, Johnson RB:Comparative metabolism of 3H-glucosamine by fibroblast populations exposed to cyclosporine. J Periodontol 65:565-567, 1994.
152.Zhu P, Ding J, Zhou J, Dong WJ, Fan CM, Chen ZN:Expression of CD147 on monocytes/macrophages in rheumatoid arthritis: its potential role in monocyte accumulation and matrix metalloproteinase production. Arthritis Res Ther 7:R1023-1033, 2005.
153.Zucker S, Hymowitz M, Rollo EE, et al.:Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158:1921-1928, 2001.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊
 
1. 表沒食子兒茶素沒食子酸脂透過抑制第六型介白素 減少 Porphyromonas gingivalis 之脂多醣體引起之牙齦纖維細胞產生第一型基質金屬蛋白酶
2. 大蒜精減少受Porphyromonas gingivalis菌之酯多醣體刺激人類牙齦纖維母細胞表現的發炎激素以及NF-κB活化作用
3. 牙周病主要致病菌Porphyromonasgingivalis促使人類牙齦纖維母細胞細胞增生及其相關蛋白降解現象探討
4. A549肺腺癌細胞在缺氧誘導下對MMP-2和MMP-9影響之探討
5. Porphyromonas gingivalis的GroEL蛋白在牙周病致病機轉之角色
6. 轉錄抑制因子B細胞誘發成熟因子1調控T細胞發育與功能之研究:基因轉殖與剔除非肥胖型糖尿病小鼠模式之運用
7. 米諾四環素加入亞甲基藍作為局部緩釋性藥物之牙周病原菌感受性及細胞毒性之研究
8. 營養礦物元素鋅和鍺對人類免疫單核球細胞株U937免疫功能影響
9. 十字花科蔬菜衍生物對Lipopolysaccharide活化巨噬細胞所誘導之血管新生作用的影響
10. 牙周病主要致病菌Porphyromonasgingivalis調控人類臍靜脈內皮細胞表現Interleukin-6及其接受器之訊息機制探討
11. 牙周致病菌Porphyromonasgingivalis、Tannerellaforsythensis對人類單核球衍生樹突狀細胞產生細胞激素的影響
12. 嚼食檳榔者之臨床牙周狀態與牙周致病菌之關係及香菸檳榔成分對牙周致病菌生長之影響
13. 潛在性牙周致病菌與氧化性迫傷於牙周病之探討
14. Resistin 在人類軟骨肉瘤細胞轉移及MMP-2蛋白表達之研究
15. 探討落葵萃取物對紫外線引起黑色素生成與發炎的影響